Lv52
1260 积分 2022-05-11 加入
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
1个月前
已完结
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
2个月前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
2个月前
已完结
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer
2个月前
已完结
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyDurvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
3个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
3个月前
已完结
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
3个月前
已完结
Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model
3个月前
已完结
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
3个月前
已完结
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
3个月前
已完结
皖公网安备34019202002308
